Zymeworks Inc. (NASDAQ:ZYME - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $18.11, but opened at $18.96. Zymeworks shares last traded at $18.68, with a volume of 340,559 shares.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on ZYME shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Zymeworks in a research report on Wednesday, October 8th. Wall Street Zen raised Zymeworks from a "buy" rating to a "strong-buy" rating in a report on Saturday. Finally, B. Riley raised Zymeworks to a "strong-buy" rating in a report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy".
View Our Latest Stock Analysis on ZYME
Zymeworks Stock Performance
The stock has a market capitalization of $1.36 billion, a P/E ratio of -18.70 and a beta of 1.51. The firm's fifty day simple moving average is $15.27.
Zymeworks (NASDAQ:ZYME - Get Free Report) last announced its earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share (EPS) for the quarter. Zymeworks had a negative return on equity of 21.59% and a negative net margin of 59.96%.The company had revenue of $4.40 million for the quarter.
About Zymeworks
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
